These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33611753)

  • 1. Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia.
    Liu X; Cheng L; He Y; Zhang R; Lu R; Zhang J; Hong M; He G; Li J
    Int J Hematol; 2021 Jul; 114(1):124-128. PubMed ID: 33611753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
    Busca A; Dellacasa C; Giaccone L; Manetta S; Biale L; Godio L; Aydin S; Festuccia M; Brunello L; Bruno B
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1765-1770. PubMed ID: 29684566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
    Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
    An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
    [No Abstract]   [Full Text] [Related]  

  • 4. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
    Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
    Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Gao Y; Gao F; Shi J; Fu H; Huang H; Zhao Y
    J Zhejiang Univ Sci B; 2021 Aug; 22(8):695-700. PubMed ID: 34414703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.
    Gong Y; Li Y; Chen X; Yang H; Zhang Y; He G; Fan L
    Ann Hematol; 2024 Aug; 103(8):3239-3242. PubMed ID: 38935319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
    McCormack PL
    Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
    Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag.
    Duncan BB; Lotter JL; Superata J; Barranta ME; Machado T; Darden I; Venugopal S; Wu CO; Abkowitz JL; Dunbar CE; Young DJ
    Br J Haematol; 2024 May; 204(5):2077-2085. PubMed ID: 38462764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
    Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
    Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
    Wang X; Liu X; Wang L; Wang JY; Li A
    Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment.
    Auner HW; Wölfler A; Beham-Schmid C; Strunk D; Linkesch W; Sill H
    Br J Haematol; 2002 Mar; 116(3):727-8. PubMed ID: 11879264
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 17. Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report.
    Huang Y; Jiang X; Han B
    Ther Adv Hematol; 2020; 11():2040620720940144. PubMed ID: 32733663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.
    Qanash H; Li Y; Smith RH; Linask K; Young-Baird S; Hakami W; Keyvanfar K; Choy JS; Zou J; Larochelle A
    Cells; 2021 Mar; 10(4):. PubMed ID: 33810313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Geng W; Kearney S; Nelson S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.